These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35660869)

  • 1. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
    Nichols WW; Bradford PA; Stone GG
    J Antimicrob Chemother; 2022 Aug; 77(9):2341-2352. PubMed ID: 35660869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.
    Nichols WW; Bradford PA; Stone GG
    J Antimicrob Chemother; 2023 Apr; 78(4):871-892. PubMed ID: 36883356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
    Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Monogue ML; Abbo LM; Rosa R; Camargo JF; Martinez O; Bonomo RA; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
    Tam VH; Merlau PR; Hudson CS; Kline EG; Eales BM; Smith J; Sofjan AK; Shields RK
    J Antimicrob Chemother; 2022 Oct; 77(11):3130-3137. PubMed ID: 36031868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The primary pharmacology of ceftazidime/avibactam: in vitro translational biology.
    Nichols WW; Bradford PA; Lahiri SD; Stone GG
    J Antimicrob Chemother; 2022 Aug; 77(9):2321-2340. PubMed ID: 35665807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
    Sy SKB; Zhuang L; Sy S; Derendorf H
    Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Schuck VJ; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):368-75. PubMed ID: 26525790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
    Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
    J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the post-antibiotic effect
    Berkhout J; Melchers MJ; van Mil AC; Lagarde CM; Nichols WW; Mouton JW
    J Chemother; 2021 Oct; 33(6):400-408. PubMed ID: 33682636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying bla
    Sleger T; Gangl E; Pop-Damkov P; Krause KM; Laud PJ; Slee AM; Nichols WW
    J Chemother; 2018 Apr; 30(2):95-100. PubMed ID: 29191131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
    Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.